Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) Covered Calls
Ascendis Pharma A/S trades in the Biotechnology industry with an IV Rank of 1.59%, low versus the past year. ASND's highest covered call setup is the $290.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 8.59% out of the money with 8 days to expiration, a 8.60% return until expiration, and a 392.58% theoretical annualized return. Across the setups shown, annualized returns run from 115.81% to 392.58% at strikes between $280.00 and $400.00, with 8 to 155 days to expiration, as of Nov 12, 2026.
Read more
Running ASND covered calls helps you generate income from Ascendis Pharma A/S shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ASND covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ASND stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ASND covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ASND covered call is worth writing.
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
| 2026-11-20 | 8 | 290.00 | 8.59 | 0.05 | 3.70 | 2298.00 | 8.60 | 392.58 | -0.02 | +0.17 | 36 | 3.65 |
| 2026-11-20 | 8 | 280.00 | 4.84 | 1.70 | 4.20 | 1463.00 | 5.48 | 249.93 | -0.64 | +0.27 | 18 | 2.50 |
| 2026-12-18 | 36 | 330.00 | 23.56 | 0.05 | 3.60 | 6298.00 | 23.58 | 239.09 | -0.02 | +0.10 | 260 | 3.55 |
| 2026-12-18 | 36 | 320.00 | 19.82 | 0.20 | 3.40 | 5313.00 | 19.89 | 201.70 | -0.07 | +0.11 | 94 | 3.20 |
| 2027-01-15 | 64 | 350.00 | 31.05 | 0.20 | 3.80 | 8313.00 | 31.13 | 177.52 | -0.07 | +0.09 | 129 | 3.60 |
| 2027-01-15 | 64 | 330.00 | 23.56 | 0.10 | 4.30 | 6303.00 | 23.60 | 134.60 | -0.04 | +0.11 | 36 | 4.20 |
| 2026-12-18 | 36 | 300.00 | 12.33 | 0.50 | 4.10 | 3343.00 | 12.52 | 126.91 | -0.19 | +0.16 | 398 | 3.60 |
| 2027-03-19 | 127 | 380.00 | 42.28 | 0.20 | 4.40 | 11313.00 | 42.36 | 121.74 | -0.07 | +0.09 | 1 | 4.20 |
| 2027-04-16 | 155 | 400.00 | 49.77 | 0.05 | 4.40 | 13298.00 | 49.79 | 117.25 | -0.02 | +0.08 | 1 | 4.35 |
| 2027-01-15 | 64 | 320.00 | 19.82 | 1.30 | 5.50 | 5423.00 | 20.31 | 115.81 | -0.49 | +0.16 | 20 | 4.20 |
As of Nov 12, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank1.59% Low
- Market cap (M$)18,085
- 52 weeks high-2.40%
- 52 weeks low46.42%
- Analyst recommendationStrong Buy
1.18 - Target price$316.26
14.84% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2027-02-10
- P/E17.73
- Future P/E24.81
- EPS (ttm)15.54
- EPS growth next 5 years—
As of Nov 13, 2026